Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
...
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
- Associated Therapies
- -
Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02809768
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 8
- Registration Number
- NCT02765256
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
- Conditions
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT02734862
- Locations
- 🇪🇸
University Hospital La Paz, Madrid, Spain
🇧🇪UCL Saint-LUC, Brussels, Belgium
🇺🇸Virginia Tech, Carillion School of Medicine, Roanoke, Virginia, United States
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT02733432
- Locations
- 🇺🇸
Women's Medical Research, Clearwater, Florida, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Seattle Women's Health, Research, Gynecology, Seattle, Washington, United States
Study of Potential for Interaction of Fluconazole With F901318
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT02730442
- Locations
- 🇬🇧
CELERION, Belfast, Northern Ireland, United Kingdom
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT02679456
- Locations
- 🇩🇴
Hospital Dr. Francisco E. Moscoso Puello, Santo Domingo, Dominican Republic
🇩🇴Instituto Dermatologico y Cirugia de Piel, Santo Domingo, Dominican Republic
Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients
- Conditions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02666716
- Locations
- 🇳🇱
Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands
🇳🇱Radboud university medical center, Nijmegen, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2019-07-05
- Target Recruit Count
- 72
- Registration Number
- NCT02663674
- Locations
- 🇺🇸
UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States
🇺🇸Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States
Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS
- Conditions
- Interventions
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 186
- Registration Number
- NCT02624453
- Locations
- 🇨🇲
Day Hospital of the Yaounde Central Hospital, Yaounde, Central Region, Cameroon
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02532192
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.